Integrating the care of HIV and TB in developing countries

Therapy

Volumn 4, Issue 6, 2007, Pages 787-796

  Wood, Robin ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Care; HIV; Integration; Program; Resource poor; TB

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; ETHAMBUTOL; ISONIAZID; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

CLINICAL TRIAL; COMORBIDITY; DEVELOPING COUNTRY; DIET THERAPY; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; DRUG POTENTIATION; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION CONTROL; INTERVENTION STUDY; MASS SCREENING; MORTALITY; MULTIDRUG RESISTANCE; OPPORTUNISTIC INFECTION; REVIEW; SHORT COURSE THERAPY; SPUTUM CULTURE; SPUTUM SMEAR; SUPERINFECTION; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION;

EID: 38049181344     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/14750708.4.6.787     Document Type: Review

References (30)

1. WHO: Global Tuberculosis Control. WHO Report 2000. WHO, Geneva, Switzerland (WHO document WHO/CDS/TB/2000.275) (2000).
2. WHO: Global Plan to Stop Tuberculosis: Phase 1, 2001-2005. Geneva, Switzerland (WHO/HTM/STB/2001.16) (2001).
3. WHO/Stop TB Partnership: Sustaining the Gains: National Self-sufficiency For Tb Drug Access: a Global Drug Facility Strategy. World Health Organization, Geneva, Switzerland (WHO/HTM/STB/2005.34) (2005).
4. WHO: Global Tuberculosis Control: Surveillance, Planning and Financing. WHO, Geneva, Switzerland (WHO/HTM/STB/2006.362) (2006).
5. WHO: Global Tuberculosis Control: WHO Report 2003. WHO Geneva, Switzerland (WHO/HTM/TB2004.331) (2004).
6. Connolly C, Reid A, Davies G, Sturm W, McAdam KP, Wilkinson D: Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa. AIDS 3(12), 1543-1547 (1999).
7. Mukadi YD, Maher D, Harries A: Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS 15(2), 143-152 (2001).
8. Harries AD, Chimzizi RB, Nyirenda TE, van Gorkom J, Salaniponi FM: Preventing recurrent tuberculosis in high HIV-prevalent areas in sub-Saharan Africa: what are the options for tuberculosis control programs? Int. J. Tuberc. Lung Dis. 7, 616-622 (2003).
9. Zignol M, Hosseini MS, Wright A. Weezenbeek CL, Nunn P, Watt CJ et al.: Global incidence of multidrug-resistant tuberculosis (2003). J. Infect. Dis. 194(4), 479-485 (2006).
10. Raviglione MC, Smith IM: XDR tuberculosis implications for global public health. N. Engl. J. Med. 356, 656-659 (2007).
11. Ghandhi NR, Mon A, Sturm AW et al.: Extensively drug resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368, 1575-1580 (2006).
12. Frieden TR, Sherman LF, Maw KL et al.: A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical features. JAMA 276(15). 1229-1235 (1996).
13. Ivers LC, Kendrick D, Doucette K: Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin. Infect. Dis. 41(2), 217-224 (2005).
14. ARTLINK writing committee: Mortality of HIV-1 patients in the first year of antiretroviral therapy: comparisons between low-income and high-income countries. Lancet 367(9513), 817-821 (2006).
15. Lawn SD, Myer L, Orrell C, Bekker K-G, Wood R: Early mortality among patients accessing a community-based antiretroviral program in South Africa: implications for program design. AIDS 19, 2141-2148 (2005).
16. Holmes CB, Wood R, Badd M et al.: CD4 decline and incidence of opportunistic infections in Cape Town, South Africa. Implications for prophylaxis and treatment. J. Acquir. Immune Defic. Syndr. 42(4), 464-469 (2006).
17. Coetzee D, Hilderbrand K, Goemaere E, Matthys F, Boelaert M: Integrating tuberculosis and HIV care in the primary care setting in South Africa. Trop. Med. Int. Health 9(6), A11-A15 (2004).
18. WHO: Global Tuberculosis Control: Surveillance. Planning, Financing: WHO Report 2007. WHO. Geneva, Switzerland (WHO/HTM/TB/2007.376) (2007)
19. Godfrey-Faussett P, Maher D, Mukadi YD, Perriens J, Raviglione M: How human immunodeficiency virus voluntary testing can contribute to tuberculosis control. Bull. WHO 80(12), 939-945 (2002).
20. WHO: Report of a 'Lessons Learnt' Workshop on the Six Pro Test Pilot Projects in Malawi, South Africa and Zambia: WHO, Geneva, Switzerland. (WHO/HTM/TB/2004.336) (2004).
21. Gasana M, Vandebriel G, Kabanda G et al.: Tuberculosis in Rwanda: challenges to reaching the targets: Bull WHO 85(5), 383-384 (2007).
22. WHO: Scaling Up HIV Testing Among TB Patients: Three Case Studies: Global Tuberculosis Control: Surveillance, Planning, Financing. WHO report. WHO, Geneva, Switzerland (WHO/HTM/TB/2007.376) (2007).
23. Miti S, Mfungwe V, Reljer P, Maher D: Integration of tuberculosis treatment in a community-based home care program for persons living with HIV/AIDS in Ndola, Zambia. Int. J. Tuberc. Lung Dis. 7(9), S92-S98 (2003).
24. Chimzizi R, Harries A: Joint tuberculosis/HIV services in Malawi: progress, challenges and the way forward. Bull. WHO 85(5), 385-386 (2007).
25. Friedland C, Harries A, Coetzee D: Implementation issues in tuberculosis/ HIV program collaboration and integration: three case studies. J. Intect Dis. 196(Suppl. 1), S114-S123 (2007).
26. Hamilton CD, Sterling T, Blumberg HM, Leonard M, McAuley J, Schlossberg D: Extensively drug-resistant tuberculosis: are we learning from history or repeating it? Clin. Infect. Dis. 45, 338-342 (2007).
27. Wells CD, Cegielski JP, Nelson LJ et al.: HIV-infection and multidrug resistant tuberculosis: the perfect storm. J. Infect. Dis. 196(Suppl. 1), S86-S107 (2007).
28. Wood R, Middelkoop K, Myer L et al.: The burden of undiagnosed tuberculosis in an African community with high HIV-prevalence: implications for TB control. Am. J. Resp. Crit. Care Med. 175(1), 87-93 (2007).
29. Lawn SD, Myer L, Bekker L-G, Wood R: Tuberculosis associated immune reconstitution disease: risk factors and impact in an antiretroviral treatment program in sub-Saharan Africa. AIDS 21(3). 335-341 (2007).
30. Lawn SD, Myer L, Harling G, Orrell C, Bekker L-G, Wood R: Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin. Inf. Dis. 43(6), 770-776 (2006).